



$\beta 2 \rightarrow$ 1-Fructans Modulate the Immune System *In Vivo* in a Microbiota-Dependent and -Independent Fashion

Floris Fransen^{1,2*}, Neha M. Sahasrabudhe², Marlies Elderman^{1,2}, Margaret Bosveld³, Sahar El Aidy⁴, Floor Hugenholtz^{1,5}, Theo Borghuis², Ben Kousemaker², Simon Winkel², Christa van der Gaast-de Jongh⁶, Marien I. de Jonge⁶, Mark V. Boekschoten^{1,7}, Hauke Smidt^{1,5}, Henk A. Schols^{1,3} and Paul de Vos^{1,2}

OPEN ACCESS

Edited by:

Mats Bemark, University of Gothenburg, Sweden

Reviewed by:

Wim Van Den Broeck, Ghent University, Belgium Siegfried Hapfelmeier, University of Bern, Switzerland Andrea Reboldi, University of Massachusetts Medical School, USA

*Correspondence:

Floris Fransen g.a.f.fransen@umcg.nl

Specialty section:

This article was submitted to Mucosal Immunity, a section of the journal Frontiers in Immunology

Received: 19 November 2016 Accepted: 30 January 2017 Published: 16 February 2017

Citation:

Fransen F, Sahasrabudhe NM, Elderman M, Bosveld M, El Aidy S, Hugenholtz F, Borghuis T, Kousemaker B, Winkel S, van der Gaast-de Jongh C, de Jonge MI, Boekschoten MV, Smidt H, Schols HA and de Vos P (2017) β2→1-Fructans Modulate the Immune System In Vivo in a Microbiota-Dependent and -Independent Fashion. Front. Immunol. 8:154. doi: 10.3389/fimmu.2017.00154 ¹ Top Institute Food and Nutrition, Wageningen, Netherlands, ²Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ³Laboratory of Food Chemistry, Wageningen University, Wageningen, Netherlands, ⁴Microbial Physiology, Groningen Biomolecular Sciences and Biotechnology Institute (GBB), University of Groningen, Groningen, Netherlands, ⁵Laboratory of Microbiology, Wageningen University, Wageningen, Netherlands, ⁶Laboratory of Pediatric Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands, ⁷Nutrition, Metabolism and Genomics Group, Division of Human Nutrition, Wageningen University, Wageningen, Netherlands

It has been shown in vitro that only specific dietary fibers contribute to immunity, but studies in vivo are not conclusive. Here, we investigated degree of polymerization (DP) dependent effects of $\beta 2 \rightarrow 1$ -fructans on immunity via microbiota-dependent and -independent effects. To this end, conventional or germ-free mice received short- or long-chain $\beta 2 \rightarrow 1$ -fructan for 5 days. Immune cell populations in the spleen, mesenteric lymph nodes (MLNs), and Peyer's patches (PPs) were analyzed with flow cytometry, genome-wide gene expression in the ileum was measured with microarray, and gut microbiota composition was analyzed with 16S rRNA sequencing of fecal samples. We found that $\beta 2 \rightarrow 1$ -fructans modulated immunity by both microbiota and microbiota-independent effects. Moreover, effects were dependent on the chain-length of the $\beta 2 \rightarrow 1$ -fructans type polymer. Both short- and long-chain $\beta 2 \rightarrow 1$ -fructans enhanced T-helper 1 cells in PPs, whereas only short-chain $\beta 2 \rightarrow 1$ -fructans increased regulatory T cells and CD11b-CD103- dendritic cells (DCs) in the MLN. A common feature after short- and long-chain $\beta 2 \rightarrow 1$ -fructan treatment was enhanced 2-alpha-L-fucosyltransferase 2 expression and other IL-22-dependent genes in the ileum of conventional mice. These effects were not associated with shifts in gut microbiota composition, or altered production of short-chain fatty acids. Both short- and long-chain $\beta 2 \rightarrow 1$ -fructans also induced immune effects in germ-free animals, demonstrating direct effect independent from the gut microbiota. Also, these effects were dependent on the chain-length of the $\beta 2 \rightarrow 1$ -fructans. Short-chain $\beta 2 \rightarrow 1$ -fructan induced lower CD80 expression by CD11b⁻CD103⁻ DCs in PPs, whereas long-chain $\beta 2 \rightarrow 1$ -fructan specifically modulated B cell responses in germ-free mice. In conclusion, support of immunity is determined by the chemical structure of $\beta 2 \rightarrow 1$ -fructans and is partially microbiota independent.

Keywords: $\beta 2 \rightarrow 1$ -fructans, prebiotics, gut microbiota, mucosal immunology, germ-free mice

INTRODUCTION

The intestinal tract contains the largest pool of immune cells in the body, which are separated by only a single layer of epithelial cells from an enormous amount of environmental stimuli, including the gut microbiota and dietary components (1). *Via* a complex of regulatory mechanisms, our immune system manages to be tolerant against food antigens and commensal microorganisms, yet a strong immune response can be raised against pathogens. The balance between tolerance and inflammatory responses is delicate and disturbances are implicated in an ever growing list of Western diseases, such as inflammatory bowel disease, allergies, diabetes, and even cancer (2). Therefore, modulation of the intestinal immune system with for example dietary fibers is considered an attractive strategy to prevent or treat these diseases (3).

Among the different dietary fibers, inulin $\beta 2 \rightarrow 1$ -fructans have been studied extensively (4). $\beta 2 \rightarrow 1$ -fructans are a heterogeneous group of polysaccharides, which can be found in several plants, but are most often commercially obtained from chicory (4). These fibers consist of several fructose subunits connected *via* $\beta 2 \rightarrow 1$ linkages, with or without a terminal glucose molecule (5). Chain-length of $\beta 2 \rightarrow 1$ -fructans can be described by the degree of polymerization (DP), which ranges from 2 to 60, referring to the number of monomers that are part of the polymeric structure. Shorter polymers with a DP < 10 are often referred to as fructooligosaccharide (FOS), whereas longer polymers with DP > 10 are usually called inulin.

 $\beta 2 \rightarrow 1$ -fructans have been shown to modulate the immune system (6). For example, short-chain $\beta 2 \rightarrow 1$ -fructans have been demonstrated to increase IgA secretion and production of IL-10 and interferon-y by CD4⁺ T cells from Peyer's patches (PPs) in mice (7, 8), whereas long-chain $\beta 2 \rightarrow 1$ -fructans induced higher numbers of dendritic cells in PPs and greater ex vivo secretion of IL-2, IL-10, and interferon-γ from spleen and mesenteric lymph node (MLN) cells after administration to rats (9). Generally, these immune effects have been attributed to the ability of $\beta 2 \rightarrow 1$ -fructans to promote the expansion of immunostimulatory bacteria in the gut, mainly Bifidobacteria and Lactobacilli (10). In addition, metabolites produced after fermentation of $\beta 2 \rightarrow 1$ -fructans by commensal gut bacteria include short-chain fatty acids (SCFAs), which dampen inflammatory responses by binding to G protein-coupled receptors GPR41, GPR43, and GPR109A expressed on different types of immune cells (11–14). Recently, we also demonstrated that $\beta 2 \rightarrow 1$ -fructans can stimulate immune cells directly in vitro via activating pattern recognition receptors such as toll-like receptors (TLRs) (15). This direct effect on immune cells in vitro is stronger with higher DP $\beta 2 \rightarrow 1$ fructans than with shorter DP $\beta 2 \rightarrow 1$ -fructans. Thus, several possible mechanisms by which $\beta 2 \rightarrow 1$ -fructans can modulate the immune system have been proposed, but the existence or contribution to immune effects in vivo is not clearly studied yet. Also, it has not been shown yet in vivo that immune modulation of $\beta 2 \rightarrow 1$ -fructans is DP dependent. This knowledge is essential as it might lead to selection of effective immune modulating dietary fibers helpful in the arms race between dietary fiber intake and Western diseases (16).

Here, we performed an *in vivo* study in mice with well-defined short and long-chain $\beta 2 \rightarrow 1$ -fructans to determine (1) whether $\beta 2 \rightarrow 1$ -fructans are able to modulate the immune system *in vivo*, (2) whether there are differences between short- and long-chain $\beta 2 \rightarrow 1$ -fructans with respect to the type of immune responses that are induced and (3) the direct effects of $\beta 2 \rightarrow 1$ -fructans on the immune system.

MATERIALS AND METHODS

Mice

Specified pathogen free conventional C57BL/6OlaHsd males of 8 weeks old were purchased from a commercial supplier (Envigo, Horst, the Netherlands), and C57BL/6OlaHsd male 8 weeks old germ-free mice were obtained from a breeding colony at the animal facility of the Radboud University (Nijmegen, the Netherlands). Samples derived from germ-free mice were routinely screened once every 2 weeks on sterility. In addition, samples from germfree mice the day before the end of the experiment were tested on sterility. All samples were screened on sterility by QM diagnostics (Nijmegen, the Netherlands) and confirmed to be sterile. At least 2 weeks before the start of $\beta 2 \rightarrow 1$ -fructans treatment all animals were receiving a D12450B diet (10% fat, Research Diet Services, Wijk bij Duurstede, the Netherlands). The mice were kept on this diet throughout the experiment. All experiments were approved by the animal ethics committee of the University of Groningen (Dierenexperimentencommissie Rijksuniversiteit Groningen, DEC-RUG).

$\beta 2 \rightarrow 1$ -Fructans

Frutalose®OFP is a highly soluble powdered short-chain $\beta 2 \rightarrow 1$ -fructan also called FOS of mainly DP2-10, produced by partial hydrolysis of chicory inulin. Frutafit®TEX! (both obtained from Sensus, Roosendaal, the Netherlands), is a powdered food ingredient of DP10-60, based on native chicory inulin. DP profiles of supplement A and B are depicted in Figure S1 in Supplementary Material.

Endotoxin levels were tested by Toxikon (Leuven, Belgium) and found to be below $0.3 \times 10^{-3} \,\mu g^{-1}$. The fructans were dissolved in sterile water and given to the conventional mice by oral gavage. In addition, to ensure sterility of these solutions before administration to germ-free mice, short-chain $\beta 2 \rightarrow 1$ -fructans were filtered with a 0.2 μ m filter and long-chain $\beta 2 \rightarrow 1$ -fructans were irradiated with 25 kGy (Synergy Health, Ede, the Netherlands), as it was to viscous for sterilization by filtration. Irridation induced some degradation of higher DP oligomers, but still significant amounts of oligomers up to DP30 were present. Sterility of the fructans after filtration or irradiation was tested by QM diagnostics (Nijmegen, the Netherlands) and confirmed to be sterile. Mice received 10 mg of these fibers or water only as a negative control by oral gavage once a day for 5 days in a row.

High-Performance Anion-Exchange Chromatography (HPAEC)

Colonic content from each mouse was first dissolved in PBS (100 mg/ml) and the supernatant was stored at -20° C after

separation from the debris by centrifugation. These samples together with cecum contents derived from the same mice as prepared in the same way were used to analyze for short- and long-chain $\beta 2 \rightarrow 1$ -fructans with HPAEC, which was performed on an ICS5000 system (Thermo Fisher Scientific, Waltham, MA, USA), equipped with a Dionex CarboPac PA-1 column $(2 \text{ mm} \times 250 \text{ mm})$ in combination with a Carbopac PA-1 guard column (2 mm \times 50 mm). Ten microliters of the samples were injected into the system using a Thermo Fischer Scientific ICS5000 autosampler. The system was equipped with pulsed amperometric detection (ED40 gold electrode). The flow rate was 0.3 ml/min, and the gradient used was 0-5 min 0.1 M NaOH, from 5 min in 40 min to 0.4 M NaOAc in 0.1 M NaOH; 5 min isocratically at 1 M NaOac in 0.1 M NaOH finally an equilibration step for 15 min at starting conditions. The software used was Chromeleon version 7 (Dionex). Monosugars and maltodextrin were used as standards.

High-Performance Liquid Chromatography (HPLC)

For SCFA analysis of cecum content, HPLC was performed to quantify butyric acid, propionic acid, acetic acid, lactic acid, and succinic acid on a Ultimate 3000 HPLC (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an autosampler, a RI-101 refractive index detector (Shodex, Kawasaki, Japan), and an ion-exclusion Aminex HPX 8H column (7.8 mm \times 300 mm) with a guard column (Bio-Rad, Hercules, CA, USA). The mobile phase was 5 mM H₂SO₄, and the flow rate was 0.6 ml/min at 65°C. Samples were injected onto the column and SCFA production was quantified.

Flow Cytometry

Spleen, PPs, and MLNs were isolated from each mouse. PPs were removed from the small intestine by tightening the patch with tweezers and cutting it with scissors, avoiding as much as possible inclusion of the surrounding intestinal epithelium. Fat tissue was carefully removed from the MLNs with a razor blade. After isolation, all organs were immediately placed in RPMI, 10% FBS, 1% Pen/Strep on ice. Single cell suspensions were obtained from all organs by crushing the organs with the plunger of a 2.5-ml syringe on 70 µm nylon cell strainers placed over a 50-ml tube. Red blood cells in spleen samples were lysed with a hypotonic lysis buffer. Cells were stained with Fixable Viability Dye eFluor 50 (eBioscience, Vienna, Austria) to exclude dead cells. Aspecific binding to FC receptors was prevented by incubating the cells with anti-CD16/32 (clone 93, Biolegend, Uithoorn, the Netherlands) for 15 min on ice. For extracellular staining, cells were incubated with the desired mixture of antibodies for 30 min on ice. After washing, cells were fixed with FACS lysing solution (BD Biosciences, Breda, the Netherlands). For intracellular staining, fixed cells were permeabilized with PERM (eBioscience, Vienna, Austria) and subsequently stained with the desired antibodies for 30 min on ice. For identification of the different T helper cell subsets, cells were stained with antibodies against: CD3e (clone 17A2), CD4 (clone GK1.5), T-bet (clone 4B10), RORyt (clone B2D), Gata-3 (clone TWAJ), CD25 (clone PC61), and Foxp3 (clone FJK-16S). Appropriate isotype controls were used to determine specificity of the staining. To identify naive or antigen-experienced T cells, the following antibodies were used: CD3e (clone 17A2), CD4 (clone GK1.5), CD8a (clone 53-6.7), CD69 (clone H1.2F3), CD44 (clone IM7), and CD62L (clone MEL-14). B-cells were stained with: CD19 (clone 6D5), B220 (clone RA-6B2), IgD (clone RTK2758), IgM (clone II/41), IgA (clone mA-6E1). For analysis of dendritic cells (DCs), other lineages were first excluded with CD3e (clone 17A2), CD19 (clone 6D5), B220 (clone RA-6B2), and NK1.1 (clone PK136). Next, DC subsets were identified with CD11c (clone HL3), MHC-II (clone M5/114.15.2), CD11b (clone M1/70), CD103 (clone 2E7), CD8a (clone 53-6.7), and CD80 (clone 16-10 A1). Samples were acquired with the FACSVerse (BD Biosciences, Breda, the Netherlands) and analyzed with Flow Jo software (Flow Jo LLC, OR, USA).

Transcriptomics

A part of the terminal ileum from each mouse was snap frozen in liquid nitrogen and stored at -80°C. RNA was isolated with the RNeasy kit (Qiagen, Valencia, CA, USA). Quantity of RNA was measured with the ND-1000 (NanoDrop Technologies, Thermo Fisher Scientific, Breda, the Netherlands) and quality of RNA was assessed with the Bioanalyzer 2100 (Agilent, Santa Clara, CA, USA). Total RNA (100 ng) was labeled utilizing the Ambion WT Expression kit (Life Technologies Ltd., Bleiswijk, the Netherlands) and the Affymetrix GeneChip WT Terminal Labeling kit (Affymetrix, Santa Clara, CA, USA). After labeling, samples were hybridized to Affymetrix GeneChip Mouse Gene 1.1 ST arrays. An Affymetrix GeneTitan Instrument was used for hybridization, washing, and scanning of the array plates. Bioconductor packages integrated in an online pipeline were used for quality control of the data (17, 18). Probe sets were redefined using current genome information (19). Probes were reorganized based on the Entrez Gene database (remapped CDF v14.1.1). Robust Multiarray Analysis preprocessing algorithm available in the Bioconductor library affyPLM (20) was used to obtain normalized expression estimates from the raw intensity values.

Fluorescence In Situ Hybridization

Another part of ileum and colon was fixed in Carnov's fixative to preserve the mucus layer. Samples were embedded in paraffin and afterward 4 μm sections of tissue were made with a microtome (Leica Biosystems, Nussloch, Germany). Paraffin was removed from the tissue slides by washing 2× with xylene for 10 min. Next, samples were washed in decreasing amounts of ethanol (99, 70, 60%) and finally in dH₂O. After washing, samples were incubated with 0.5 µg universal bacterial probe EUB338 (5'-GCTGCCTCCCGTAGGAGT-3') or segmented filamentous bacteria (SFB)-specifc probe SFB1008 (5'-GCGAGCTTCCCTCATTACAAGG-3') conjugated on the 5' end with Alexa 488 (Eurogentec, Maastricht, the Netherlands) in hybridization solution (20 mM TRIS-HCl, pH 7.4, 0.9 M NaCl, 0.1% weight/volume SDS) at 50°C overnight in a humid environment. The next day, the samples were washed in FISH washing buffer (20 mM TRIS-HCl, pH 7.4, 0.9 M NaCl) for

20 min. Tissue slides were then washed $2\times$ for 10 min with PBS and incubated with DAPI solution (30 nM) for 5 min to visualize nuclei of the epithelial cells. After washing $2\times$ with PBS, samples were mounted with mounting medium. Data were acquired with a SP8 Leica confocal microscope (Leica Microsystems, Son, the Netherlands), and images were processed afterward with Imaris software (Bitplane, Zurich, Switzerland).

Microbiota Analysis

Fresh fecal samples obtained just after defecation were collected from all conventional mice before the start of fiber treatment. In addition, colonic content samples from these mice were collected at the end of the experiment. All samples were snap frozen in liquid nitrogen and stored at -80°C. These samples were used for 16S rRNA gene analysis for microbiota profiling with barcoded amplicons from the V1-V2 region of 16S rRNA genes generated using a 2-step PCR strategy that reduces the impact of barcoded primers on the outcome of microbial profiling (21). DNA extraction was performed using a combination of the bead-beating-plus column method and the Maxwell 16 Tissue LEV Total RNA purification kit (Promega, Leiden, the Netherlands). Beating of the fecal pellets took place as described before (22) but with STAR (Stool transport and recovery) buffer (Roche, Basel Switzerland). After centrifugation, 250 µl supernatant was taken for the Maxwell 16 Tissue LEV Total RNA Purification Kit, and the DNA was eluted in 50 µl DNAse free water. Twenty nanograms of DNA were used for the amplification of the 16S rRNA gene with primers 27F-DegS and 338R I + 338R II for 25 cycles as described before (23), only primers had a Universal Tag (UniTag) linkers attached; UniTag I (forward) and II (reverses) (I-GAGCCGTAGCCAGTCTGC; II-GCCGTGACCGTGACATCG). The first PCR was performed in a total volume of 50 μ l containing 1 \times HF buffer (Finnzymes, Vantaa, Finland), 1 µl dNTP Mix (10 mM; Promega, Leiden, the Netherlands), 1 U of Phusion® Hot Start II High-Fidelity DNA polymerase (Finnzymes Vantaa, Finland), 500 nM of the 27F-DegS primer (23, 24) that was appended with UniTag 1 at the 5' end, 500 nM of an equimolar mix of two reverse primers, 338R I and II (24) based on three previously published probes EUB 338 I, II, and III (23), that were 5'-extended with UniTag 2, and 0.2–0.4 ng/µl of template DNA. The sequence of the UniTags were selected to have a GC content of ~66% and a minimal tendency to form secondary structures, including hairpin loops, heterodimers, and homodimers as assessed by the IDTDNA Oligoanalyzer 3.1 (Integrated DNA Technologies). Moreover, sequences were selected that had no matches in 16S rRNA gene databases [based on results of the "TestProbe" tool offered by the SILVA rRNA database project (25) using the SSU r117 database], and no prefect matches in genome databases with the Primer-BLAST tool (http://www.ncbi.nlm.nih.gov/ tools/primer-blast/). The size of the PCR products (~375 bp) was confirmed by gel electrophoresis using 5 µl of the amplification reaction mixture on a 1% (w/v) agarose gel containing $1 \times$ SYBR® Safe (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA). Five microliters of these PCR products were taken to add adaptors and a 8-nt sample-specific barcode in an additional

five cycle PCR amplification. This second PCR was performed in a total volume of 100 μ l containing 1× HF buffer, dNTP Mix 2 U of Phusion® Hot Start II High-Fidelity DNA polymerase, 500 nM of a forward and reverse primer equivalent to the Unitag 1 and UniTag 2 sequences, respectively, that were each appended with an 8 nt sample-specific barcode (Hermes et al., in preparation) at the 5' end. PCR products were purified with the magnetic beads (MagBio, London, UK) according to the HighPrepTM protocol of the manufactures instructions using 20 µl Nuclease Free Water (Promega Leiden, the Netherlands) and quantified using the Qubit (Life Technologies, Bleiswijk, the Netherlands). Purified PCR products were mixed in approximately equimolar amounts and concentrated by the magnetic beads as the purification before. Purified amplicon pools were 250 bp paired-end sequenced using Illumina Miseq (GATC-Biotech, Konstanz, Germany).

The Illumina Miseq data analysis was carried out with a workflow employing the Quantitative Insights Into Microbial Ecology (QIIME) pipeline (26) and a set of in-house scripts as described before for Illumina Hiseq 16S rRNA gene sequences (Hermes et al., in preparation). The set of in-house scripts processed the reads as follows: reads were filtered for not matching barcodes; otu picking and chimera removal was done *via* matching the sequences to the Silva 111 database, with only one mismatch allowed, and a biom and with clustalw a multiple alignment and phylogenetic tree file was generated. Further outputs were generated *via* QIIME, such as filtered reads per sample, PD whole tree diversity measurements and the level 1–6 taxonomic distributions with relative abundances.

Statistics

Flow cytometry data are expressed as means, error bars represent SEM. To verify whether there were significant differences between the groups, one way ANOVA was performed followed by the Dunnett's multiple comparisons test. All tests were performed with Graphpad software (Prism, La Jolla, CA, USA).

Differentially expressed probe sets were identified using linear models, applying moderated T-statistics that implemented empirical Bayes regularization of SEs (27). A Bayesian hierarchical model was used to define an intensity-based moderated T-statistic, which takes into account the degree of independence of variances relative to the degree of identity and the relationship between variance and signal intensity (28).

Statistical tests for gut microbiota composition were performed using R and Calypso (29), where the count data were not normally distributed and variances between groups were not equal, the Mann–Whitney U test was used.

RESULTS

$\beta 2 \rightarrow 1$ -Fructans Modulate the Mucosal Immune System *In Vivo*

We demonstrated previously that inulin $\beta 2 \rightarrow 1$ -fructans stimulate immune cells directly and in a DP-dependent manner *in vitro* (15). In this *in vivo* study in mice, the immune effects of chemically characterized short (DP2-10) and long-chain chain $\beta 2 \rightarrow 1$ -fructans (DP10-60) were compared. To this end, conventional mice received these fibers by oral gavage once a day for 5 days. Effects were studied in the PPs, MLNs, and spleen.

Th1, Th2, Th17, and Treg cells in the different organs were compared between mice treated with the two $\beta 2 \rightarrow 1$ -fructans and controls (Figure 1A). No differences were found in the spleen (data not shown). However, in the PPs, both short and long-chain $\beta 2 \rightarrow 1$ -fructan induced a higher number of Th1 cells (p < 0.05) compared to controls. In addition, in MLNs, shortchain $\beta 2 \rightarrow 1$ -fructan but not long-chain $\beta 2 \rightarrow 1$ -fructan treatment resulted in higher percentages of Treg cells (p < 0.05) and CD4⁺ T cells expressing the activation marker CD69 (p < 0.05). Next, we assessed the influence of $\beta 2 \rightarrow 1$ -fructan treatment on B-cells in these tissues. No differences were observed in B cells in any organ tested (data not shown). Finally, considering the important role of DCs in initiating and modulating adaptive immune responses, we also evaluated the effect of $\beta 2 \rightarrow 1$ -fructan treatment on DCs (Figure 1B). Strikingly, mice treated with short-chain but not the mice treated with long-chain $\beta 2 \rightarrow 1$ -fructan had an increase in CD11b⁻CD103⁻ DCs in the MLNs (p < 0.01) and a decrease in CD11b⁺CD103⁺ DCs (p < 0.05). No differences were found in spleen or PPs (data not shown).

Thus, $\beta 2 \rightarrow 1$ -fructans can modulate the immune system locally in the PP and MLN *in vivo* in a DP-dependent fashion. Only short-chain $\beta 2{\rightarrow}1\text{-}fructan$ modulated DC and Treg numbers in MLNs.

$\beta 2 {\rightarrow} 1\text{-}Fructans$ Induce Chain-Length Dependent Changes in Gene Expression in the lleum

To investigate the different impact in an unbiased manner, effects of the two $\beta 2 \rightarrow 1$ -fructans on the host whole-genome expression of ileal tissue were studied with microarray. The ileum is assumed to be the location where $\beta 2 \rightarrow 1$ -fructans interact with the mucosa (6). Treatment with both short and long-chain $\beta 2 \rightarrow 1$ -fructan induced significant differential gene expression of approximately 100 genes in the ileum (*p*-value < 0.01, fold-change > 1.3) compared to controls (Figure 2A). Remarkably, the majority of affected genes were uniquely and differently regulated by either short- or long-chain $\beta 2 \rightarrow 1$ -fructans (**Figures 2B,C**). There was only a minimal overlap in the induced responses by these $\beta 2 \rightarrow 1$ -fructans. One of these genes was galactoside 2-alpha-L-fucosyltransferase 2 (Fut2), an enzyme involved in glycosylation. It was among the top-10 most upregulated genes by both short- and long-chain $\beta 2 \rightarrow 1$ -fructans (Figure 2D). Recently, it has been demonstrated that Fut2 is upregulated by microbiota-dependent stimulation of IL-22 production by type 3 innate lymphoid cells, which in turn







stimulates colonization resistance against pathogens (30). That IL-22 is regulated by both short- and long-chain $\beta 2 \rightarrow 1$ -fructans was further confirmed by the observation that (i) genes known to be upregulated in epithelial cells by IL-22 (31) were strongly enriched in the top-10 most upregulated genes (**Figure 2D**) and (ii) that several of these genes clustered together after hierarchical cluster analysis (**Figure 2C**). However, short-chain $\beta 2 \rightarrow 1$ -fructan seemed to induce a stronger response, reflected by

higher expression of microbiota-dependent genes such as Fut2, SAA1, Retnlb, and Duox2 (**Figures 2C,D**). As upregulation of the IL-22-Fut2 axis is assumed to be gut microbiota dependent (30), these results suggest that the effects of $\beta 2 \rightarrow 1$ -fructans on gene expression in the ileum are caused by differences in effects on gut microbiota. Therefore, we next studied and compared the microbiota composition in the mice treated with short- and long-chain $\beta 2 \rightarrow 1$ -fructans.

Short- and Long-Chain $\beta 2 \rightarrow 1$ -Fructans Did Not Alter Gut Microbiota Composition

As SFB promote production of IL-22 and upregulation of Fut2 (30), we first studied the ileum of short- and long-chain $\beta 2 \rightarrow 1$ -fructan treated animals for possible differences in colonization by SFB (**Figure 3A**). Although we observed an overall higher density of microbiota after FISH staining (**Figure 3B**), especially in animals receiving short-chain $\beta 2 \rightarrow 1$ -fructans, we never found SFB in the ileum in any sample. Also by applying 16S rDNA sequencing in fecal samples, we excluded promotion of SFB in the $\beta 2 \rightarrow 1$ -fructans-treated mice (data not shown), which suggest that other mechanisms must be responsible for FUT2 upregulation.

Since $\beta 2 \rightarrow 1$ -fructans have been shown to modulate gut microbiota composition (10), we analyzed gut microbiota composition with 16S rDNA sequencing in fecal samples before and after treatment with the dietary fibers (**Figure 4A**). No significant differences were found in any specific bacterial group after treatment (data not shown). Moreover, in agreement with the SFB-specific FISH staining, SFB was not detected in any of the samples (data not shown). Redundancy analysis suggested that gut microbiota composition was similar between the groups before treatment, as expected (**Figure 4B**). The samples from the three groups posttreatment separated into three different clusters, suggesting that $\beta 2 \rightarrow 1$ -fructans had some effect on the composition of the microbial community, but this separation was not significant (**Figure 4B**).

$\beta 2 \rightarrow$ 1-Fructans Are Degraded in the Gut But Do Not Induce Enhanced SCFA Production

Next, despite the absence of differences in microbiota composition between short- and long-chain $\beta 2 \rightarrow 1$ -fructan-treated mice, we studied possible differences in immune active SCFA production as explanation for the observed immune differences. However, concentrations of butyrate, propionate, acetate, lactic acid, and succinic acid in cecal samples were not different, nor enhanced by the two $\beta 2 \rightarrow 1$ -fructans (**Figure 5B**). As it might be suggested that this might be caused by lack of fermentation of the $\beta 2 \rightarrow 1$ -fructans, we quantified the fructans in the colon and cecum of $\beta 2 \rightarrow 1$ -fructan-treated mice by HPAEC. Both $\beta 2 \rightarrow 1$ fructans were undetectable, indicating completely utilization by the gut microbiota (**Figure 5A**, only plot of short-chain fructan is shown).

$\beta 2 \rightarrow 1$ -Fructans Modulate Immune Responses in Germ-Free Mice

As we could not find pronounced difference in short and longchain $\beta 2 \rightarrow 1$ -fructans induced effects on microbiota or its degradation products, we determined and compared the impact of the two $\beta 2 \rightarrow 1$ -fructans on the mucosal immunity in germ-free mice.

As expected, $\beta 2 \rightarrow 1$ -fructans were not degraded in the intestine of germ-free mice (**Figure 6A**), and no SCFAs could be detected (data not shown). Analysis of immune cells population in the







FIGURE 4 | $\beta 2 \rightarrow 1$ -fructan treatment does not alter gut microbiota composition. Fecal samples (n = 4-5 per group) were collected before or after treatment with short-chain $\beta 2 \rightarrow 1$ -fructans, long-chain $\beta 2 \rightarrow 1$ -fructans, or water (not treated/control). Bacterial DNA was isolated and analyzed with 16S rDNA sequencing. Numbers indicate individual mice before or after treatment, indicated with "F" and "C," respectively. (A) Distribution of the different bacterial groups at the phylum level for all samples. (B) Redundancy analysis (RDA) for all samples at the genus level.



FIGURE 5 | $\beta 2 \rightarrow 1$ -fructans are degraded in the gut but do not increase short-chain fatty acid (SCFA) levels. (A) Colonic and cecal content of mice that received short-chain $\beta 2 \rightarrow 1$ -fructans was analyzed with high-performance anion-exchange chromatography and compared to short-chain $\beta 2 \rightarrow 1$ -fructan. (B) Cecal samples from mice (n = 5 per group) that received short-chain $\beta 2 \rightarrow 1$ -fructans (short), long-chain $\beta 2 \rightarrow 1$ -fructans (long), or water (NT) were analyzed with high-performance liquid chromatography to quantify butyric acid, propionic acid, acetic acid, lactic acid, and succinic acid and succinic acid were not detected (data not shown).



PPs, MLNs, and spleens was performed in the same fashion as in conventional mice. Th1, Th2, Th17, and Treg cells were not influenced by $\beta 2 \rightarrow 1$ -fructans in the absence of microbiota (data not shown). In contrast, we did observe effects on B-cells and DCs in $\beta 2 \rightarrow 1$ -fructan-treated germ-free mice, and the effects were DP dependent. Long-chain $\beta 2 \rightarrow 1$ -fructans induced enhanced numbers of IgD¹⁰IgM^{hi} B-cells in the MLNs (p < 0.05, **Figure 6B**) but not in the PPs or spleen (data not shown), while short-chains did not have such an effect. DCs in PPs were only modulated by short-chain $\beta 2 \rightarrow 1$ -fructans as expression of the activation marker CD80 was lower in PP DCs that did not express CD11b or CD103 (p < 0.05) (**Figure 6C**). Only graphs of regulated cells are shown.

Microbiota-Independent $\beta 2 \rightarrow 1$ -Fructan-Induced Changes in Gene Expression in the lleum

Also, the ileum of $\beta 2 \rightarrow 1$ -fructan treated germ-free mice was studied by whole-genome expression with microarray. We

found that both short- and long-chain $\beta 2 \rightarrow 1$ -fructans modulate the gene expression in the ileum in the absence of the gut microbiota (**Figure 7A**). First, the gene profiles of short-chain $\beta 2 \rightarrow 1$ -fructan-treated germ-free animals were compared to that of treated mice with a conventional microbiome to determine unique microbiota-dependent and microbiota-independent effects. The same was done for long-chain $\beta 2 \rightarrow 1$ -fructan. After that, we compared the DP-dependent effects in the germ-free animals.

As shown in **Figure 7B**, there was only minor overlap between the genes affected in conventional and germ-free mice for both short and long-chain fructans, suggesting that $\beta 2 \rightarrow 1$ -fructans modulate different pathways by direct interaction and by microbiota-dependent effects.

Strikingly, when studying DP-dependent effects in the mice there was also minimal overlap between differential gene expression induced by short and the long-chain treated germ-free mice (**Figure 7C**). This illustrates that similarly to what we observed



in conventional mice, chain-length of $\beta 2 \rightarrow 1$ -fructans is key in determining the type of induced response.

Long-Chain $\beta 2 \rightarrow 1$ -Fructan Modulates B-Cell Response in Germ-Free Mice

A heatmap of the 40 most differentially expressed genes in the ileum of germ-free mice after treatment with short or irradiated long-chain inulin further confirmed the presence of gene clusters specifically modulated by either short- and long-chain $\beta 2 \rightarrow 1$ -fructan (Figure 8A). In particular, long-chain $\beta 2 \rightarrow 1$ -fructan seemed to modulate B-cell responses, since several genes involved in antibody production were differentially expressed, including a strong upregulation of IgD and CD20 (Figure 8B). These data correspond to the flow cytometry data, where we observed an increase in IgD^{lo}IgM^{hi} B-cells in the MLNs of germ-free mice after inulin treatment.

DISCUSSION

The structure-effector relationship between dietary fibers and health benefits *in vivo* is an area that deserves further exploration.

Differences in immunomodulation by non-digestible dietary fibers is generally considered to depend on differences in stimulation of immunomodulatory bacteria and/or their fermentation products such as SCFA (33). Several studies have shown that a diet with a high content of non-digestible fiber leads to higher levels of SCFAs in the intestine (34). However, we did not observe any differences in SCFA levels after fructan treatment. Therefore, it seems unlikely that the observed effects are mediated by SCFAs. Possibly 5 days of treatment is too short to enhance SCFA production.

We recently demonstrated *in vitro* that the dietary fibers $\beta 2 \rightarrow 1$ -fructans can activate immune cells directly in a chainlength dependent manner (15). Here, we demonstrate to the best of our knowledge for the first time that direct effects of dietary fibers on immunity also occur *in vivo*. Our germ-free mice study confirms that direct effects of $\beta 2 \rightarrow 1$ -fructans are also *in vivo* chain-length dependent.

One of the major findings of our study is that the chain-length of $\beta 2 \rightarrow 1$ -fructans is crucial in dictating the type of immune response *in vivo*. In conventional mice both fibers enhanced the number of Th1 cells in the PPs, but only short-chain $\beta 2 \rightarrow 1$ -fructan treatment increased the number of Tregs and CD11b⁻CD103⁻ DCs in



the MLNs. Therefore, our data seem to suggest that in response to short-chain $\beta 2 \rightarrow 1$ -fructans CD11b⁻CD103⁻ DCs migrate from the LP to the MLN to induce Tregs. Also, the whole-genome gene expression data indicate stronger immune responses in the ileum after short-chain $\beta 2 \rightarrow 1$ -fructan treatment compared to long-chain $\beta 2 \rightarrow 1$ -fructans. These differences might reflect the fact that short-chain $\beta 2 \rightarrow 1$ -fructans are fermented earlier and more read-ily in the gastro-intestinal tract than long-chain $\beta 2 \rightarrow 1$ -fructans due to the shorter polymeric structure (35, 36). The highest concentration of immune cells can be found in the ileum, where the mucus layer is much thinner compared to the colon (1). Several bacterial species that occupy this niche are known to interact with the immune system (37). Targeting these bacteria with relatively easily digestible short-chain $\beta 2 \rightarrow 1$ -fructans might therefore be an effective strategy for modulation of immune responses.

A second, and very important finding is the demonstration of effects of $\beta 2 \rightarrow 1$ -fructans on the immune system in the absence

of the microbiota by using germ-free mice. In these mice, we observed a clear difference between short- and long-chain $\beta 2 \rightarrow 1$ -fructan. These differences could be due to differential direct interactions with pattern recognition receptors such as TLRs on immune cells, as described previously (15). Long-chain $\beta 2 \rightarrow 1$ -fructans, but not short-chain $\beta 2 \rightarrow 1$ -fructans, induced strong modulation of B-cell responses in germ-free mice. Longchain $\beta 2 \rightarrow 1$ -fructans have been shown to activate TLR2 more strongly in vitro (15) and could have activated TLRs expressed on B-cells more strongly than for short-chain fructans in vivo. TLR ligands are well known for their ability to activate B-cells (38). Alternatively, long-chain $\beta 2 \rightarrow 1$ -fructans could have activated B-cells in antigen-specific manner in germ-free mice. Presumably, 5 days of treatment with long-chain $\beta 2 \rightarrow 1$ -fructans would be too short to detect specific antibodies. However, we did observe upregulation of IgD and CD20 in the ileum in germ-free mice treated with long-chain $\beta 2 \rightarrow 1$ -fructans, which may indicate expansion of antigen-specific B-cells, before class-switching to another isotype such as IgA.

To the best of our knowledge, we demonstrate for the first time that $\beta 2 \rightarrow 1$ -fructan treatment can enhance Fut2 expression, which is an enzyme involved in fucosylation of epithelial cells in the gut. This effect was observed with both DPs. Fut2 was recently shown to be induced by microbiota-dependent (especially SFB) stimulation of IL-22 production by type 3 innate lymphoid cells, which promoted colonization resistance against mucosal pathogens (30, 31, 39). Here, we observed that several genes such as Fut2, SAA1, Retnlb, and Duox2 that were previously shown to be induced by IL-22 (31) were highly upregulated in the ileum after treatment with $\beta 2 \rightarrow 1$ -fructans. Fut2 induced upregulation by $\beta 2 \rightarrow 1$ -fructans may therefore be a novel mechanism by which these dietary fibers contribute to improved colonization of bacteria and reported health effects (6).

Although we excluded that SFB colonization was responsible for Fut2 expression, we do not exclude that $\beta 2 \rightarrow 1$ -fructans enhanced other gut microbes that induced Fut2 expression. Other commensals, such as *Bacteroides*, have been shown to induce epithelial fucosylation as well (40, 41). However, we did not find a significant shift in gut microbiota composition in fecal samples after $\beta 2 \rightarrow 1$ -fructan treatment. However, FISH staining of ileum samples suggests higher number of bacteria in the ileum after $\beta 2 \rightarrow 1$ -fructan treatment. Therefore, it remains possible that $\beta 2 \rightarrow 1$ -fructans induced local expansion of specific bacterial species in the small intestine, which subsequently enhanced expression of Fut2 in the epithelium.

In humans, application of $\beta 2 \rightarrow 1$ -fructans to induce upregulation of Fut2 for enhancement of resistance against mucosal pathogens (30, 31, 39) might be more complex than in mice. Approximately 20% of the human population lacks a functional copy of Fut2, which are referred to as non-secretors (42). The role of Fut2 in development of several diseases has been demonstrated by comparing secretor and non-secretors. The Fut2 non-secretors have a different microbiota composition with less *Bifidobacteria* (43) and are less susceptible to enteric viruses (44), but are more susceptible to Crohn's disease (45). Fut2 manipulation with dietary fibers such as $\beta 2 \rightarrow 1$ -fructans may therefore be an interesting approach to alleviate symptoms or frequency of intestinal diseases in the 80% of secretors.

In conclusion, our data suggest that rational design of $\beta 2 \rightarrow 1$ -fructans formulations with different chain-lengths is a promising and probably a necessary approach to achieve the desired effect in different target populations. We demonstrate that effects can be both microbiota dependent and independent. Moreover, although dietary fibers are considered as beneficial for health in general, our data demonstrate that at least in case of $\beta 2 \rightarrow 1$ -fructans this depends on the chain length of the fiber.

ETHICS STATEMENT

This study was carried out in accordance with the recommendations of FELESA guidelines and the ethical committee for animal experiments from the University of Groningen (DEC-RUG). The protocol was approved by the he ethical committee for animal experiments from the University of Groningen (DEC-RUG).

AUTHOR CONTRIBUTIONS

FF and PV designed experiments and wrote the manuscript. FF, NS, ME, MB, FH, TB, BK, and SW performed experiments. SA, FH, and HS analyzed microbiota composition data. MB and HAS provided and analyzed HPAEC and HPLC data. MVB generated and analyzed microarray data. CJ and MJ provided reagents and resources. PV supervised the project.

ACKNOWLEDGMENTS

Authors would like to thank Jenny Jansen, Mike Peters, and Stefanie Schonfeld for excellent technical assistance.

FUNDING

This study was funded by the Top Institute of Food and Nutrition (TIFN).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at http://journal.frontiersin.org/article/10.3389/fimmu.2017.00154/ full#supplementary-material.

FIGURE S1 | Degree of polymerization (DP) distribution in short- and long-chain $\beta 2 \rightarrow 1$ -fructan. DP distribution in short-chain $\beta 2 \rightarrow 1$ -fructan (short) and long-chain $\beta 2 \rightarrow 1$ -fructan.

FIGURE S2 | FACS plots T cells. Gating strategy and representative FACS plots (mesenteric lymph nodes sample) for identifying T cell subsets. (A) Among CD3⁺CD4⁺ T cells the percentage of Tregs (Foxp3⁺CD25⁺), Th1 cells (T-bet⁺), Th17 cells (RORgt⁺), and Th2 cells (GATA-3⁺) was identified. Percentage of cells stained with isotype control was subtracted to determine the percentage of true positive cells. (B) Percentages of naïve (CD44^{to}CD62L^{to}), memory cells (CD44^{to}CD62L^{to}), and effector cells (CD44^{to}CD62L^{to}) among CD3⁺CD4⁺ and CD3⁺CD8⁺ cells. In addition, the percentage of CD69⁺ cells was identified among CD3⁺CD4⁺ and CD3⁺CD8⁺ cells.

FIGURE S3 | FACS plots B cells and dendritic cells (DCs). Gating strategy and representative FACS plots (mesenteric lymph nodes sample) for identifying B cell and DC subsets. (A) B cells were identified as CD19⁺B220⁺ and further divided in IgD^{I+}IgM^{I+}, IgD^{I+}IgM^{I+}, or IgD^{I+}IgM^{I+}. In addition, IgA-producing B cells were identified as IgD⁻¹IgA⁺ (B) DCs were identified as lineage negative (CD3⁻CD19⁻B220⁻NK1.1⁻) and CD11c^{I+}IMHC-II^{I+}. These cells were further divided into four subsets based on the expression of CD11b and CD103. In addition, CD80 expression was assessed for each DC subset.

FIGURE S4 | Segmented filamentous bacteria (SFB) FISH staining. A

representative image (one mouse treated with short-chain $\beta 2 \rightarrow 1$ -fructans) of ileum samples fixed in Carnoy's fixative that were stained with SFB-specifc probe SFB1008 conjugated to Alexa Fluor 488 (green) and DAPI (blue). Some green spots were identified, but they lacked the typical morphology of SFB.

REFERENCES

- Mowat AM, Agace WW. Regional specialization within the intestinal immune system. Nat Rev Immunol (2014) 14:667–85. doi:10.1038/nri3738
- Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Genet (2012) 13:260–70. doi:10.1038/nrg3182
- Klaenhammer TR, Kleerebezem M, Kopp MV, Rescigno M. The impact of probiotics and prebiotics on the immune system. *Nat Rev Immunol* (2012) 12:728–34. doi:10.1038/nri3312
- Roberfroid MB. Inulin-type fructans: functional food ingredients. J Nutr (2007) 137:2493S–502S.
- Gibson GR, Probert HM, Loo JV, Rastall RA, Roberfroid MB. Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. *Nutr Res Rev* (2004) 17:259–75. doi:10.1079/NRR200479
- Vogt L, Meyer D, Pullens G, Faas M, Smelt M, Venema K, et al. Immunological properties of inulin-type fructans. *Crit Rev Food Sci Nutr* (2015) 55:414–36. doi:10.1080/10408398.2012.656772
- Nakamura Y, Nosaka S, Suzuki M, Nagafuchi S, Takahashi T, Yajima T, et al. Dietary fructooligosaccharides up-regulate immunoglobulin A response and polymeric immunoglobulin receptor expression in intestines of infant mice. *Clin Exp Immunol* (2004) 137:52–8. doi:10.1111/j.1365-2249. 2004.02487.x
- Hosono A, Ozawa A, Kato R, Ohnishi Y, Nakanishi Y, Kimura T, et al. Dietary fructooligosaccharides induce immunoregulation of intestinal IgA secretion by murine Peyer's patch cells. *Biosci Biotechnol Biochem* (2003) 67:758–64. doi:10.1271/bbb.67.758
- Ryz NR, Meddings JB, Taylor CG, Manhart N, Spittler A, Bergmeister H, et al. Long-chain inulin increases dendritic cells in the Peyer's patches and increases ex vivo cytokine secretion in the spleen and mesenteric lymph nodes of growing female rats, independent of zinc status. *Br J Nutr* (2009) 101:1653. doi:10.1017/S000711450812342X
- Roberfroid M, Gibson GR, Hoyles L, McCartney AL, Rastall R, Rowland I, et al. Prebiotic effects: metabolic and health benefits. *Br J Nutr* (2010) 104(Suppl):S1–63. doi:10.1017/S0007114510003363
- Julia V, Macia L, Dombrowicz D. The impact of diet on asthma and allergic diseases. Nat Rev Immunol (2015) 15:308–22. doi:10.1038/nri3830
- Meijer K, de Vos P, Priebe MG. Butyrate and other short-chain fatty acids as modulators of immunity: what relevance for health? *Curr Opin Clin Nutr Metab Care* (2010) 13:715–21. doi:10.1097/MCO.0b013e32833eebe5
- Macia L, Tan J, Vieira AT, Leach K, Stanley D, Luong S, et al. Metabolitesensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. *Nat Commun* (2015) 6:6734. doi:10.1038/ncomms7734
- Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. *Science* (2013) 341:569–73. doi:10.1126/science. 1241165
- Vogt L, Ramasamy U, Meyer D, Pullens G, Venema K, Faas MM, et al. Immune modulation by different types of β2→1-fructans is toll-like receptor dependent. *PLoS One* (2013) 8:e68367. doi:10.1371/journal.pone.0068367
- Sonnenburg ED, Sonnenburg JL. Starving our microbial self: the deleterious consequences of a diet deficient in microbiota-accessible carbohydrates. *Cell Metab* (2014) 20:779–86. doi:10.1016/j.cmet.2014.07.003
- Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. *Genome Biol* (2004) 5:R80. doi:10.1186/gb-2004-5-10-r80
- Lin K, Kools H, de Groot PJ, Gavai AK, Basnet RK, Cheng F, et al. MADMAX management and analysis database for multiple ~omics experiments. J Integr Bioinform (2011) 8:160. doi:10.2390/biecoll-jib-2011-160
- Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, et al. Evolving gene/ transcript definitions significantly alter the interpretation of GeneChip data. *Nucleic Acids Res* (2005) 33:e175. doi:10.1093/nar/gni179
- Bolstad BM, Collin F, Simpson KM, Irizarry RA, Speed TP. Experimental design and low-level analysis of microarray data. *Int Rev Neurobiol* (2004) 60:25–58. doi:10.1016/S0074-7742(04)60002-X
- Berry D, Ben Mahfoudh K, Wagner M, Loy A. Barcoded primers used in multiplex amplicon pyrosequencing bias amplification. *Appl Environ Microbiol* (2011) 77:7846–9. doi:10.1128/AEM.05220-11

- Yu Z, Morrison M. Improved extraction of PCR-quality community DNA from digesta and fecal samples. *Biotechniques* (2004) 36:808–12.
- Van den Bogert B, Erkus O, Boekhorst J, de Goffau M, Smid EJ, Zoetendal EG, et al. Diversity of human small intestinal *Streptococcus* and *Veillonella* populations. *FEMS Microbiol Ecol* (2013) 85:376–88. doi:10.1111/1574-6941.12127
- Van den Bogert B, de Vos WM, Zoetendal EG, Kleerebezem M. Microarray analysis and barcoded pyrosequencing provide consistent microbial profiles depending on the source of human intestinal samples. *Appl Environ Microbiol* (2011) 77:2071–80. doi:10.1128/AEM.02477-10
- Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. *Nucleic Acids Res* (2013) 41:D590–6. doi:10.1093/nar/ gks1219
- Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, et al. QIIME allows analysis of high-throughput community sequencing data. *Nat Methods* (2010) 7:335–6. doi:10.1038/nmeth.f.303
- 27. Storey JD, Tibshirani R. Statistical significance for genomewide studies. *Proc Natl Acad Sci U S A* (2003) 100:9440–5. doi:10.1073/pnas.1530509100
- Sartor MA, Tomlinson CR, Wesselkamper SC, Sivaganesan S, Leikauf GD, Medvedovic M. Intensity-based hierarchical Bayes method improves testing for differentially expressed genes in microarray experiments. *BMC Bioinformatics* (2006) 7:538. doi:10.1186/1471-2105-7-538
- Ainsworth D, Krause L, Bridge T, Torda G, Raina J-B, Zakrzewski M, et al. The coral core microbiome identifies rare bacterial taxa as ubiquitous endosymbionts. *ISME J* (2015) 9:2261–74. doi:10.1038/ismej.2015.39
- Goto Y, Obata T, Kunisawa J, Sato S, Ivanov II, Lamichhane A, et al. Innate lymphoid cells regulate intestinal epithelial cell glycosylation. *Science* (2014) 345:1254009. doi:10.1126/science.1254009
- Pham TAN, Clare S, Goulding D, Arasteh JM, Stares MD, Browne HP, et al. Epithelial IL-22RA1-mediated fucosylation promotes intestinal colonization resistance to an opportunistic pathogen. *Cell Host Microbe* (2014) 16:504–16. doi:10.1016/j.chom.2014.08.017
- Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. *Cell* (2009) 139:485–98. doi:10.1016/j.cell.2009.09.033
- Vieira AT, Teixeira MM, Martins FS. The role of probiotics and prebiotics in inducing gut immunity. *Front Immunol* (2013) 4:445. doi:10.3389/ fimmu.2013.00445
- Kim CH, Park J, Kim M. Gut microbiota-derived short-chain fatty acids, T cells, and inflammation. *Immune Netw* (2014) 14:277–88. doi:10.4110/ in.2014.14.6.277
- 35. Ito H, Takemura N, Sonoyama K, Kawagishi H, Topping DL, Conlon MA, et al. Degree of polymerization of inulin-type fructans differentially affects number of lactic acid bacteria, intestinal immune functions, and immunoglobulin A secretion in the rat cecum. J Agric Food Chem (2011) 59:5771–8. doi:10.1021/jf200859z
- Ito H, Wada T, Ohguchi M, Sugiyama K, Kiriyama S, Morita T. The degree of polymerization of inulin-like fructans affects cecal mucin and immunoglobulin A in rats. *J Food Sci* (2008) 73:H36–41. doi:10.1111/j.1750-3841.2008. 00686.x
- Aidy SE, van den Bogert B, Kleerebezem M. The small intestine microbiota, nutritional modulation and relevance for health. *Curr Opin Biotechnol* (2015) 32:14–20. doi:10.1016/j.copbio.2014.09.005
- Pasare C, Medzhitov R. Control of B-cell responses by toll-like receptors. Nature (2005) 438:364–8. doi:10.1038/nature04267
- Pickard JM, Maurice CF, Kinnebrew MA, Abt MC, Schenten D, Golovkina TV, et al. Rapid fucosylation of intestinal epithelium sustains hostcommensal symbiosis in sickness. *Nature* (2014) 514:638–41. doi:10.1038/ nature13823
- Hooper LV, Xu J, Falk PG, Midtvedt T, Gordon JI. A molecular sensor that allows a gut commensal to control its nutrient foundation in a competitive ecosystem. *Proc Natl Acad Sci U S A* (1999) 96:9833–8. doi:10.1073/ pnas.96.17.9833
- Coyne MJ, Reinap B, Lee MM, Comstock LE. Human symbionts use a host-like pathway for surface fucosylation. *Science* (2005) 307:1778–81. doi:10.1126/ science.1106469
- 42. Koda Y, Tachida H, Pang H, Liu Y, Soejima M, Ghaderi AA, et al. Contrasting patterns of polymorphisms at the ABO-secretor gene (FUT2) and plasma

{{alpha}}(1,3)fucosyltransferase gene (FUT6) in human populations. *Genetics* (2001) 158:747–56.

- Wacklin P, Mäkivuokko H, Alakulppi N, Nikkilä J, Tenkanen H, Räbinä J, et al. Secretor genotype (FUT2 gene) is strongly associated with the composition of Bifidobacteria in the human intestine. *PLoS One* (2011) 6:e20113. doi:10.1371/ journal.pone.0020113
- Kambhampati A, Payne DC, Costantini V, Lopman BA. Host genetic susceptibility to enteric viruses: a systematic review and metaanalysis. *Clin Infect Dis* (2016) 62(1):11–8. doi:10.1093/cid/civ873
- McGovern DPB, Jones MR, Taylor KD, Marciante K, Yan X, Dubinsky M, et al. Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease. *Hum Mol Genet* (2010) 19:3468–76. doi:10.1093/hmg/ddq248

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Fransen, Sahasrabudhe, Elderman, Bosveld, El Aidy, Hugenholtz, Borghuis, Kousemaker, Winkel, van der Gaast-de Jongh, de Jonge, Boekschoten, Smidt, Schols and de Vos. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.